Summit Therapeu ADR (SMMT)

$24.17 +3.05 (14.44%)
Market Cap 16.18B
Revenue (ttm) 0.00
Net Income (ttm) -1.08B
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 5,529,126
Avg Vol 2,438,430
Day's Range N/A - N/A
Shares Out 776.02M
Stochastic %K 72%
Beta -1.36
Analysts Strong Sell
Price Target $30.80

Company Profile

Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies. Its lead development candidate is ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis for the treatment of non-small lung cancer (NSCLC) and colorectal cancer (CRC). The company has also combined ivonescimab with chemotherapy, which is in phase III clinical...

Industry: Biotechnology
Sector: Healthcare
Phone: 305 203 2034
Address:
601 Brickell Key Drive, Suite 1000, Miami, United States
PatrickandFrankie
PatrickandFrankie Apr. 16 at 7:31 PM
$SMMT looks like I got that right yesterday.. not that I am trading my shares .. holding till the buyout myself but you be you
0 · Reply
_Meyers2times
_Meyers2times Apr. 16 at 7:30 PM
$DIS $ETN $SMMT that
0 · Reply
EingeLTrade
EingeLTrade Apr. 16 at 7:16 PM
$SMMT 👌
0 · Reply
TJknows
TJknows Apr. 16 at 7:15 PM
$SMMT
0 · Reply
TheTeamArctic
TheTeamArctic Apr. 16 at 6:59 PM
$MBOT $SMMT $EONR $TPET mco
0 · Reply
TruthBroker2
TruthBroker2 Apr. 16 at 6:52 PM
$SMMT
0 · Reply
TJknows
TJknows Apr. 16 at 6:20 PM
$SMMT Fueling up for round two?
0 · Reply
arist442
arist442 Apr. 16 at 6:16 PM
$SMMT Pretty impressive on a down day for biotechs. Hope it's not a short squeeze. I'd rather some good news leaked ; )
0 · Reply
_TeamArctic
_TeamArctic Apr. 16 at 5:42 PM
$PATH $MBOT $SMMT $EONR TO
0 · Reply
TruthBroker2
TruthBroker2 Apr. 16 at 5:27 PM
$SMMT
0 · Reply
Latest News on SMMT
Summit Therapeutics Has Scarcity Value In A Crowded Drug Race: Analyst

Apr 8, 2026, 2:27 PM EDT - 8 days ago

Summit Therapeutics Has Scarcity Value In A Crowded Drug Race: Analyst

Multiple Ivonescimab Data Sets from Phase III Studies in Advanced NSCLC Patient Populations to be Featured at ELCC 2026

Mar 27, 2026, 8:15 AM EDT - 20 days ago

Multiple Ivonescimab Data Sets from Phase III Studies in Advanced NSCLC Patient Populations to be Featured at ELCC 2026

Summit Therapeutics to Present at Upcoming Investor Conferences

Feb 26, 2026, 6:45 PM EST - 6 weeks ago

Summit Therapeutics to Present at Upcoming Investor Conferences

Summit Therapeutics Reports Financial Results and Operational Progress for the Fourth Quarter and Year Ended December 31, 2025

Feb 23, 2026, 4:05 PM EST - 7 weeks ago

Summit Therapeutics Reports Financial Results and Operational Progress for the Fourth Quarter and Year Ended December 31, 2025

Summit Therapeutics to Host Fourth Quarter and Full Year 2025 Financial Results & Operational Progress Call on February 23, 2026

Feb 17, 2026, 5:05 PM EST - 2 months ago

Summit Therapeutics to Host Fourth Quarter and Full Year 2025 Financial Results & Operational Progress Call on February 23, 2026

Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jan 30, 2026, 4:30 PM EST - 2 months ago

Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Summit Therapeutics Announces U.S. FDA Acceptance of Biologics License Application (BLA) Seeking Approval for Ivonescimab in Combination with Chemotherapy in Treatment of Patients with EGFRm NSCLC Post-TKI Therapy

Jan 29, 2026, 7:30 AM EST - 2 months ago

Summit Therapeutics Announces U.S. FDA Acceptance of Biologics License Application (BLA) Seeking Approval for Ivonescimab in Combination with Chemotherapy in Treatment of Patients with EGFRm NSCLC Post-TKI Therapy

Summit Therapeutics Announces Clinical Trial Collaboration with GSK to Evaluate Ivonescimab in Combination with GSK's B7-H3 Antibody Drug Conjugate (ADC)

Jan 12, 2026, 6:15 AM EST - 3 months ago

Summit Therapeutics Announces Clinical Trial Collaboration with GSK to Evaluate Ivonescimab in Combination with GSK's B7-H3 Antibody Drug Conjugate (ADC)

GSK

Summit Therapeutics Announces Submission of Biologics License Application (BLA) to U.S. FDA Seeking Approval for Ivonescimab in Combination with Chemotherapy in 2L+ Treatment of Patients with EGFRm NSCLC

Jan 12, 2026, 6:00 AM EST - 3 months ago

Summit Therapeutics Announces Submission of Biologics License Application (BLA) to U.S. FDA Seeking Approval for Ivonescimab in Combination with Chemotherapy in 2L+ Treatment of Patients with EGFRm NSCLC

Summit Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

Jan 6, 2026, 7:30 AM EST - 3 months ago

Summit Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

Ivonescimab Plus Chemotherapy Demonstrates a Statistically Significant Benefit in Overall Survival with a Hazard Ratio of 0.74 in 2L+ Treatment of Patients with EGFRm NSCLC in HARMONi-A Study Conducted by Akeso in China

Nov 7, 2025, 9:00 AM EST - 5 months ago

Ivonescimab Plus Chemotherapy Demonstrates a Statistically Significant Benefit in Overall Survival with a Hazard Ratio of 0.74 in 2L+ Treatment of Patients with EGFRm NSCLC in HARMONi-A Study Conducted by Akeso in China

Overall Survival Data from HARMONi-A, Featuring Ivonescimab in Combination with Chemotherapy vs. Chemotherapy in 2L+ Treatment of Patients with EGFRm NSCLC in China, to be Showcased at SITC 2025

Oct 31, 2025, 7:00 AM EDT - 5 months ago

Overall Survival Data from HARMONi-A, Featuring Ivonescimab in Combination with Chemotherapy vs. Chemotherapy in 2L+ Treatment of Patients with EGFRm NSCLC in China, to be Showcased at SITC 2025

Summit Therapeutics Raises $500 Million in Private Placement

Oct 22, 2025, 8:00 AM EDT - 6 months ago

Summit Therapeutics Raises $500 Million in Private Placement

What's Going On With Summit Therapeutics Stock On Monday?

Oct 20, 2025, 10:05 AM EDT - 6 months ago

What's Going On With Summit Therapeutics Stock On Monday?

Summit Therapeutics Reports Financial Results and Operational Progress for the Third Quarter and Nine Months Ended September 30, 2025

Oct 20, 2025, 6:45 AM EDT - 6 months ago

Summit Therapeutics Reports Financial Results and Operational Progress for the Third Quarter and Nine Months Ended September 30, 2025

Ivonescimab with Chemotherapy Reduced the Risk of Disease Progression or Death by 40% Compared to Tislelizumab (PD-1 Inhibitor) Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in the HARMONi-6 Study Conducted by Akeso in China

Oct 19, 2025, 10:30 AM EDT - 6 months ago

Ivonescimab with Chemotherapy Reduced the Risk of Disease Progression or Death by 40% Compared to Tislelizumab (PD-1 Inhibitor) Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in the HARMONi-6 Study Conducted by Akeso in China

Summit Therapeutics Announces Expansion of Ivonescimab Global Phase III Development Program with HARMONi-GI3 Study in 1L Colorectal Cancer

Oct 17, 2025, 7:00 AM EDT - 6 months ago

Summit Therapeutics Announces Expansion of Ivonescimab Global Phase III Development Program with HARMONi-GI3 Study in 1L Colorectal Cancer

Summit Therapeutics to Host ESMO Data Update & Third Quarter Earnings Call on October 20, 2025

Oct 15, 2025, 7:00 AM EDT - 6 months ago

Summit Therapeutics to Host ESMO Data Update & Third Quarter Earnings Call on October 20, 2025

HARMONi-6, Featuring Ivonescimab Combined with Chemotherapy vs. Tislelizumab Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in China, to be Showcased in Presidential Symposium at ESMO 2025

Sep 24, 2025, 7:00 AM EDT - 7 months ago

HARMONi-6, Featuring Ivonescimab Combined with Chemotherapy vs. Tislelizumab Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in China, to be Showcased in Presidential Symposium at ESMO 2025

Summit Therapeutics: Buy the Next Dip Amid Clinical Breakthrough Potential

Sep 17, 2025, 10:54 PM EDT - 7 months ago

Summit Therapeutics: Buy the Next Dip Amid Clinical Breakthrough Potential

Summit Therapeutics Inc. Investigated by the Portnoy Law Firm

Sep 16, 2025, 4:31 PM EDT - 7 months ago

Summit Therapeutics Inc. Investigated by the Portnoy Law Firm

CORRECTION -- Summit Therapeutics Inc. Investigated by the Portnoy Law Firm

Sep 10, 2025, 12:43 AM EDT - 7 months ago

CORRECTION -- Summit Therapeutics Inc. Investigated by the Portnoy Law Firm

Top 3 Health Care Stocks You'll Regret Missing In Q3

Sep 9, 2025, 9:12 AM EDT - 7 months ago

Top 3 Health Care Stocks You'll Regret Missing In Q3

LNAI

Summit Therapeutics' Lung Cancer Drug Under Dark Clouds As Keytruda Challenger Shows Regional Data Differences

Sep 8, 2025, 8:28 AM EDT - 7 months ago

Summit Therapeutics' Lung Cancer Drug Under Dark Clouds As Keytruda Challenger Shows Regional Data Differences

New Fortress Energy Posts Q2 Loss, Joins Summit Therapeutics And Other Big Stocks Moving Lower In Monday's Pre-Market Session

Sep 8, 2025, 8:10 AM EDT - 7 months ago

New Fortress Energy Posts Q2 Loss, Joins Summit Therapeutics And Other Big Stocks Moving Lower In Monday's Pre-Market Session

NFE

Ivonescimab Plus Chemotherapy Demonstrates Consistent Global Benefit: HARMONi Data Update Shows OS HR=0.78, Nominal P=0.0332

Sep 7, 2025, 6:08 AM EDT - 7 months ago

Ivonescimab Plus Chemotherapy Demonstrates Consistent Global Benefit: HARMONi Data Update Shows OS HR=0.78, Nominal P=0.0332

Longer-Term Follow-Up of Western Patients Showed Improving, Favorable Trend in Overall Survival in Global Phase III HARMONi Clinical Trial for Ivonescimab Plus Chemotherapy in 2L+ EGFRm NSCLC

Sep 7, 2025, 3:30 AM EDT - 7 months ago

Longer-Term Follow-Up of Western Patients Showed Improving, Favorable Trend in Overall Survival in Global Phase III HARMONi Clinical Trial for Ivonescimab Plus Chemotherapy in 2L+ EGFRm NSCLC

Summit Therapeutics to Host Update Call at WCLC 2025 on September 8, 2025

Sep 3, 2025, 7:00 AM EDT - 8 months ago

Summit Therapeutics to Host Update Call at WCLC 2025 on September 8, 2025

Summit, Akeso Report Lung Cancer Survival Boost With Ivonescimab, A Rival To Merck's Keytruda Multi-Billion Dollar Franchise, Says Analyst

Aug 27, 2025, 2:43 PM EDT - 8 months ago

Summit, Akeso Report Lung Cancer Survival Boost With Ivonescimab, A Rival To Merck's Keytruda Multi-Billion Dollar Franchise, Says Analyst

Ivonescimab Data from Global Phase III HARMONi Study to be Showcased at Presidential Symposium at WCLC 2025

Aug 14, 2025, 7:00 AM EDT - 8 months ago

Ivonescimab Data from Global Phase III HARMONi Study to be Showcased at Presidential Symposium at WCLC 2025

Summit Therapeutics Reports Financial Results and Operational Progress for the Second Quarter Ended June 30, 2025

Aug 11, 2025, 5:03 PM EDT - 8 months ago

Summit Therapeutics Reports Financial Results and Operational Progress for the Second Quarter Ended June 30, 2025

SMMT Investors Have Opportunity to Join Summit Therapeutics Inc. Fraud Investigation with the Schall Law Firm

Jul 14, 2025, 3:00 PM EDT - 9 months ago

SMMT Investors Have Opportunity to Join Summit Therapeutics Inc. Fraud Investigation with the Schall Law Firm

Revolution Medicines and Summit Therapeutics Enter Into Clinical Collaboration to Evaluate Combinations of Three RAS(ON) Inhibitors With Ivonescimab in RAS Mutant Tumors

Jun 30, 2025, 8:00 AM EDT - 10 months ago

Revolution Medicines and Summit Therapeutics Enter Into Clinical Collaboration to Evaluate Combinations of Three RAS(ON) Inhibitors With Ivonescimab in RAS Mutant Tumors

RVMD

Summit Therapeutics to Participate in the 46th Annual Goldman Sachs Global Healthcare Conference

Jun 5, 2025, 8:00 AM EDT - 11 months ago

Summit Therapeutics to Participate in the 46th Annual Goldman Sachs Global Healthcare Conference

Is SMMT Stock A Buy After Its Recent Plunge?

Jun 2, 2025, 9:10 AM EDT - 11 months ago

Is SMMT Stock A Buy After Its Recent Plunge?

Summit Therapeutics Study Is a Win for China Biopharma Deals. Why the Stock Is Down.

May 30, 2025, 9:27 AM EDT - 11 months ago

Summit Therapeutics Study Is a Win for China Biopharma Deals. Why the Stock Is Down.

Summit Therapeutics' Closely-Watched Lung Cancer Study Of Ivonescimab Misses Overall Survival Endpoint

May 30, 2025, 9:01 AM EDT - 11 months ago

Summit Therapeutics' Closely-Watched Lung Cancer Study Of Ivonescimab Misses Overall Survival Endpoint

Ivonescimab Plus Chemotherapy Demonstrates Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival in Patients with EGFR-Mutant Non-Small Cell Lung Cancer after EGFR TKI Therapy in Global Study

May 30, 2025, 6:00 AM EDT - 11 months ago

Ivonescimab Plus Chemotherapy Demonstrates Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival in Patients with EGFR-Mutant Non-Small Cell Lung Cancer after EGFR TKI Therapy in Global Study

Final Trade: NVS, XLU and SMMT

May 1, 2025, 6:20 PM EDT - 1 year ago

Final Trade: NVS, XLU and SMMT

NVS XLU

Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2025

May 1, 2025, 4:09 PM EDT - 1 year ago

Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2025

Why Is Summit Therapeutics Stock Trading Higher On Monday?

Apr 28, 2025, 1:00 PM EDT - 1 year ago

Why Is Summit Therapeutics Stock Trading Higher On Monday?

What's Going On With Summit Therapeutics Stock On Friday?

Apr 25, 2025, 3:14 PM EDT - 1 year ago

What's Going On With Summit Therapeutics Stock On Friday?

Interim Overall Survival Analysis Requested from Chinese Health Authorities Shows a Clinically Meaningful, Positive Trend Favoring Ivonescimab Compared to Pembrolizumab in PD-L1 Positive Advanced NSCLC from HARMONi-2 Study Conducted by Akeso in China

Apr 25, 2025, 2:50 PM EDT - 1 year ago

Interim Overall Survival Analysis Requested from Chinese Health Authorities Shows a Clinically Meaningful, Positive Trend Favoring Ivonescimab Compared to Pembrolizumab in PD-L1 Positive Advanced NSCLC from HARMONi-2 Study Conducted by Akeso in China

Summit Therapeutics to Host First Quarter 2025 Financial Results & Operational Progress Call on May 1, 2025

Apr 24, 2025, 4:15 PM EDT - 1 year ago

Summit Therapeutics to Host First Quarter 2025 Financial Results & Operational Progress Call on May 1, 2025

Why Is Summit Therapeutics Stock Soaring On Wednesday?

Apr 23, 2025, 3:47 PM EDT - 1 year ago

Why Is Summit Therapeutics Stock Soaring On Wednesday?

Ivonescimab in Combination with Chemotherapy Achieves Statistically Significant Superiority in PFS vs. Tislelizumab (PD-1 Inhibitor) Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in HARMONi-6 Study Conducted by Akeso in China

Apr 23, 2025, 6:15 AM EDT - 1 year ago

Ivonescimab in Combination with Chemotherapy Achieves Statistically Significant Superiority in PFS vs. Tislelizumab (PD-1 Inhibitor) Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in HARMONi-6 Study Conducted by Akeso in China

PatrickandFrankie
PatrickandFrankie Apr. 16 at 7:31 PM
$SMMT looks like I got that right yesterday.. not that I am trading my shares .. holding till the buyout myself but you be you
0 · Reply
_Meyers2times
_Meyers2times Apr. 16 at 7:30 PM
$DIS $ETN $SMMT that
0 · Reply
EingeLTrade
EingeLTrade Apr. 16 at 7:16 PM
$SMMT 👌
0 · Reply
TJknows
TJknows Apr. 16 at 7:15 PM
$SMMT
0 · Reply
TheTeamArctic
TheTeamArctic Apr. 16 at 6:59 PM
$MBOT $SMMT $EONR $TPET mco
0 · Reply
TruthBroker2
TruthBroker2 Apr. 16 at 6:52 PM
$SMMT
0 · Reply
TJknows
TJknows Apr. 16 at 6:20 PM
$SMMT Fueling up for round two?
0 · Reply
arist442
arist442 Apr. 16 at 6:16 PM
$SMMT Pretty impressive on a down day for biotechs. Hope it's not a short squeeze. I'd rather some good news leaked ; )
0 · Reply
_TeamArctic
_TeamArctic Apr. 16 at 5:42 PM
$PATH $MBOT $SMMT $EONR TO
0 · Reply
TruthBroker2
TruthBroker2 Apr. 16 at 5:27 PM
$SMMT
0 · Reply
IBBullish
IBBullish Apr. 16 at 5:07 PM
$IBRX meanwhile $SMMT flies on China data. SMH
1 · Reply
TJknows
TJknows Apr. 16 at 4:44 PM
$SMMT
0 · Reply
PickemDeep22
PickemDeep22 Apr. 16 at 4:40 PM
$SMMT remember this was 50% higher last April… she’s got room to run
1 · Reply
TruthBroker2
TruthBroker2 Apr. 16 at 4:30 PM
$SMMT Be Looking Good
0 · Reply
SmokeWagon
SmokeWagon Apr. 16 at 4:28 PM
$SMMT !!!
0 · Reply
SmokeWagon
SmokeWagon Apr. 16 at 4:17 PM
$SMMT And Here We…. Go!!!
0 · Reply
DragonAlgo
DragonAlgo Apr. 16 at 3:58 PM
🐉 $SMMT CALL — DragonAlgo® Signal Contract: SMMT CALL Expiry: 2026-04-17 | Strike: $20.00 | Type: CALL Option Plan (premium): Entry: $3.50 Stop: $2.52 TP1: $4.55 TP2: $5.95 TP3: $8.40 Rules-based execution profile. 🔗 https://dragonalgo.com
0 · Reply
TruthBroker2
TruthBroker2 Apr. 16 at 3:53 PM
$ABBV $ISRG $SMMT $PLSE
0 · Reply
db59
db59 Apr. 16 at 3:37 PM
$SMMT What’s driving share price? 1) Blistering hot market. NASDQ and S&P at all-time highs. 2) Shorts covering. Substantial squeeze (margin calls) starts at $24+. 3) Near-term catalyst (HARMONi-3 interim PFS results in Q2). Anticipation of positive results drives value and a desire to capture profits.
0 · Reply
LoveRetailFroth
LoveRetailFroth Apr. 16 at 3:22 PM
$AMLX Good Morning ☕️ This 💎 will get to $35 quickly here. 52 Week high today. AMX0114 data any day & AVEXTIDE Phase 3 in 90 days 🚀 $RXRX $SANA $SMMT $TEM
0 · Reply
InItToWinIt100
InItToWinIt100 Apr. 16 at 3:19 PM
$SMMT $25 target https://www.trade-ideas.com/share.php?code=cReidas8Bb2EYtCO6ng9V7mjZYXnSSwV
1 · Reply
BigBeardTrader
BigBeardTrader Apr. 16 at 3:16 PM
$SMMT Pays to be patient.
0 · Reply